Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
BRIDGEWATER, N.J., Feb. 28, 2017 -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, announced today that Will Lewis, president and chief executive officer of Insmed, will present at the Cowen and Company 37th Annual Health Care Conference in Boston, MA on Tuesday, March 7, 2017 at 11:20 a.m. ET.
Mr. Lewis’ presentation will be webcast live and can be accessed by visiting the investor relations section of the company’s website at www.insmed.com. The webcast will be archived for a period of 90 days following the conclusion of the live event.
About Insmed
Insmed Incorporated is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases. The company is advancing a global phase 3 clinical study of ARIKAYCE (liposomal amikacin for inhalation) for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC), a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. There are currently no approved inhaled products specifically indicated for the treatment of refractory NTM lung infections caused by MAC in the United States or European Union (EU). Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of DPP1 with therapeutic potential in non-CF bronchiectasis, and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare disorders, including pulmonary arterial hypertension (PAH). For more information, visit www.insmed.com.
Investor Contact: Laura Perry or Heather Savelle Argot Partners 212-600-1902 [email protected] [email protected]
